November 2025: A Month of Surprises and Setbacks in Endocrinology
While November 2025 may have seemed quiet on the surface, it was a month of significant developments in the world of endocrinology, with breakthroughs, disappointments, and controversies that demand attention. But here's where it gets controversial... Could the failure of a highly anticipated Alzheimer's treatment be a blessing in disguise, paving the way for more targeted therapies? And this is the part most people miss: the subtle yet profound shift of GLP-1 receptor agonists into uncharted territories like nephrology and cardiology.
The month kicked off with a mix of emotions as Novo Nordisk experienced a rollercoaster ride. On one hand, their investigational drug, amycretin, demonstrated remarkable weight loss outcomes in patients with type 2 diabetes (T2D), outperforming placebo and sparking hope for a new era in diabetes management. However, the question remains: can amycretin's success be replicated in larger, more diverse populations? On the other hand, the company faced a setback with semaglutide, which failed to significantly slow Alzheimer's disease progression, raising doubts about its potential in this area. Yet, a meta-analysis revealed semaglutide's cardiorenal benefits in chronic kidney disease, regardless of diabetes status, highlighting the complexity of these therapies.
And now, for the game-changer... Eloralintide, a once-weekly amylin receptor agonist, emerged as a promising contender in weight management, showing superior mean weight reductions in obese patients with comorbidities. But what does this mean for the future of obesity treatment? Could we be witnessing the rise of a new class of weight-loss medications? Meanwhile, the Diabetes Dialogue podcast shed light on critical updates, including Dexcom's 15-day G7 sensor launch and significant price adjustments for Ozempic and Wegovy, which may impact accessibility for patients.
In another surprising twist, tirzepatide showed promise in type 1 diabetes (T1D), improving weight loss, glycemic control, and reducing insulin doses, all while maintaining a favorable safety profile. But here's the million-dollar question: can tirzepatide's success in T1D be translated to other diabetes-related complications? As we navigate these developments, it's clear that November 2025 was far from uneventful. From the highs of amycretin's success to the lows of semaglutide's Alzheimer's setback, this month has left us with more questions than answers. What are your thoughts on these groundbreaking findings? Do you think the shift of GLP-1 agonists into nephrology and cardiology is a game-changer, or is it too early to tell? Share your insights and join the conversation – we want to hear from you!
